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Introduction
Both Sweet’s syndrome and pyoderma gangraenosum are
neutrophilic dermatoses with abrupt onset of painful skin
lesions. In Sweet’s syndrome systemic symptoms such as
fever, headache and leucocytosis together with painful
skin papules are often seen. Corticosteroid therapy is
often sufficient treatment. Pyoderma gangraenosum is
characterized by the development of painful ulcerative
skin lesions and can be managed with anti-TNFa
(infliximab).
Objectives
We report a symptom overlap between these two condi-




A 7-month-old girl, first child of non-consanguineous
Danish parents, was admitted with multiple painful
inflammatory skin lesions. Pregnancy and delivery were
without complications. The child was born at term with a
birth weight of 3970 g and received her first vaccination
(diphtheria, pertussis, tetanus, haemophilus influenzae and
polio) 3 months old without any complication. Two weeks
after she received the second vaccination 6 months old
she developed a 3 x 4 cm large skin lesion consistent with
pyoderma gangraenosum, at the injection site on her right
thigh. The following month she developed numerous
½-1 cm large, round, necrotic, painful ulcerations on the
extremities and the neck. CRP was elevated to 106 mg/L;
haematology and immunoglobulins were normal. Biopsy
showed lesions with diffuse, neutrophilic infiltrates
but without granuloma or vasculitic abnormalities; the
findings were therefore compatible with Sweet’s syndrome.
On high-dose corticosteroid treatment with pulse methyl-
prednisolone (10 mg/kg/day for 3 days) followed by oral
prednisolone (2mg/kg/day) the initial response was
marked. However, on repeated attempts of tapering off
prednisolone she flared on even high doses of predniso-
lone (2 mg/kg/d) and azathioprine. She then received
treatment with infliximab (7-8 mg/kg) resulting in a rapid
and dramatic response within few days and went into
remission and corticosteroids were finally tapered off.
After 6 doses of infliximab the treatment was stopped.
Remission has currently lasted one year after termination
of medical treatment.
Conclusion
This case shows that the clinicians have to be aware of
the overlap between Sweet’s syndrome and pyoderma
gangraenosum in order to identify patients that might
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